STAT
MARCH 18, 2024
The biggest enticement that large pharmacy benefit managers offer to the employers that hire them is drug rebates — a steady stream of money sent back to their clients, a tangible symbol of the discounts that PBMs are able to wrangle out of pharmaceutical companies.
STAT
JUNE 1, 2023
In a bold move, Coherus BioSciences plans to sell a biosimilar version of Humira — one of the world’s best-selling medicines — at a steep discount, and will work with Mark Cuban’s generic drug company to make the medicine available directly to consumers for even less.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
DECEMBER 21, 2023
To ring the register, a pharmaceutical company may create a patent thicket , which involves filing dozens of patents that, in some cases, add little value to their medicines but extend precious monopolies. As a result, a drug company can quickly add a number of patents that can be used to protect its medicines from would-be rivals.
STAT
OCTOBER 2, 2024
The effort comes after CVS Health and Cigna — which own CVS Caremark and Express Scripts, respectively — launched subsidiaries that are striking “co-manufacturing” deals with companies that make biologic medicines and lower-cost versions known as biosimilars.
STAT
JANUARY 31, 2023
Underscoring the opaque and confusing nature of pharmaceutical pricing, Amgen announced long-awaited pricing for its biosimilar version of Humira – the world’s best-selling medicine – and the numbers suggest the biggest winners may be health insurers and others in the supply chain, but not patients.
STAT
NOVEMBER 19, 2024
Analysts expect that Merck might be able to continue to charge a higher price for the in-office version while competition from biosimilar medicines pushes down the price for Keytruda’s existing formulation.
Drug Patent Watch
MARCH 13, 2025
Navigating the Complex World of Biosimilar Supply Chains As the demand for biosimilars continues to grow, so do the challenges associated with their supply chains. One of the biggest hurdles biosimilar manufacturers face is the need to replicate complex biological processes with precision and consistency.
Expert insights. Personalized for you.
363 
Let's personalize your content